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ABSTRACT
A major drawback of tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) is that
primitive CML cells are able to survive TKI-mediated BCR-ABL inhibition, leading to disease persistence in
patients. Investigation of strategies aiming to inhibit alternative survival pathways in CML is therefore critical.
We have previously shown that a nonspeciﬁc pharmacological inhibition of autophagy potentiates TKI-induced
death in Philadelphia chromosome-positive cells. Here we provide further understanding of how speciﬁc and
pharmacological autophagy inhibition affects nonmitochondrial and mitochondrial energy metabolism and
reactive oxygen species (ROS)-mediated differentiation of CML cells and highlight ATG7 (a critical component
of the LC3 conjugation system) as a potential speciﬁc therapeutic target. By combining extra- and intracellular
steady state metabolite measurements by liquid chromatography-mass spectrometry with metabolic ﬂux
assays using labeled glucose and functional assays, we demonstrate that knockdown of ATG7 results in
decreased glycolysis and increased ﬂux of labeled carbons through the mitochondrial tricarboxylic acid cycle.
This leads to increased oxidative phosphorylation and mitochondrial ROS accumulation. Furthermore,
following ROS accumulation, CML cells, including primary CML CD34C progenitor cells, differentiate toward the
erythroid lineage. Finally, ATG7 knockdown sensitizes CML progenitor cells to TKI-induced death, without
affecting survival of normal cells, suggesting that speciﬁc inhibitors of ATG7 in combination with TKI would
provide a novel therapeutic approach for CML patients exhibiting persistent disease.
KEYWORDS
ATG7; autophagy; chronic
myeloid leukemia; energy
metabolism; erythroid
differentiation; glycolysis;
oxidative phosphorylation;
reactive oxygen species;
tyrosine kinase inhibitor
Introduction
Chronic myeloid leukemia (CML) arises as a consequence of a
reciprocal translocation between the long arms of chromosomes
9 and 22 t(9;22)(q34;q11) that occurs within a haemopoietic
stem cell (HSC).1 This generates the Philadelphia chromosome
which carries the chimeric BCR-ABL gene coding for a fusion
oncoprotein with constitutive tyrosine kinase activity.2,3 The
known molecular pathogenesis of CML has facilitated the devel-
opment of ABL-speciﬁc tyrosine kinase inhibitors (TKIs), such
as imatinib (ﬁrst generation), dasatinib, nilotinib, bosutinib (sec-
ond generation) and ponatinib (third generation).4 TKI treat-
ment has proven to be superior to previous forms of therapy by
inducing cytogenetic and molecular responses in the majority of
patients with newly diagnosed chronic phase (CP) CML.5 In
turn, this has enabled 10% to 20% of patients to enter drug
discontinuation trials6 and raised expectations that cure might
be achievable in CML. However, with time problems of drug
resistance and disease persistence have emerged in the clinic.7,8
It is now generally accepted that disease persistence is caused by
primitive CML cells that are relatively insensitive to imatinib
and other TKIs and can survive for prolonged periods of time
despite complete BCR-ABL kinase inhibition.9,10 This implies
that the majority of CML patients need to continue TKI treat-
ment indeﬁnitely while facing the risk of experiencing drug
toxicity, TKI-resistance, relapse and/or disease progression.4
Further investigation into novel targetable survival pathways
that are selectively active in CML cells is therefore essential.
Constitutively active BCR-ABL mimics growth factor stimula-
tion by activating signaling pathways, such as the PI3K-AKT-
MTOR pathway,11 that is frequently deregulated in various
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cancers and crucial for leukemogenesis.12,13 In addition, this path-
way plays important roles in the regulation of HSCs, energy
metabolism, mitochondrial activity, and autophagy.14,15 Auto-
phagy (referring to macroautophagy) is an evolutionarily con-
served catabolic process where double-membrane vesicles,
termed autophagosomes, engulf cellular components and trans-
port them to lysosomes for degradation by lysosomal hydrolases.
The cargo often consists of harmful cellular material that can lead
to DNA damage and genomic instability if not removed.16 Recy-
cling of these intracellular components therefore promotes sur-
vival by maintaining cellular homeostasis and can also serve as an
alternative source of energy during periods of metabolic stress, as
well as growth factor or nutrient deprivation.17 Active tyrosine
kinases, such as SRC and BCR-ABL, are entrapped within auto-
phagosomes in transformed cells, suggesting that cancer cells
may use autophagy to regulate and accommodate elevated levels
of highly active oncogenic kinases.18,19 Autophagy can also lead
to degradation of mitochondria (mitophagy), organelles in which
pyruvate is broken down in the tricarboxylic acid (TCA) cycle to
supply reducing agents (NADH and FADH2) for oxidative phos-
phorylation (OXPHOS) and ATP production.20 Therefore
autophagy may be an important regulator of cellular metabolic
capabilities.
We have previously shown that autophagy is rapidly induced
following TKI treatment in CML cells and pharmacological
autophagy inhibition, using the nonspeciﬁc autophagy inhibitor
hydroxychloroquine (HCQ; inhibits autophagy at a late stage by
preventing the fusion of autophagosomes and lysosomes),
enhances the effect of TKI treatment in CML cells, including
primary CD34C stem or progenitor cells.21,22 Intrinsically linked
to autophagy, energy metabolism has received signiﬁcant atten-
tion over the past decade, particularly since it has become
apparent that transformation from a normal cell to a cancerous
one requires metabolic changes to fuel the high energy demands
of cancer cells. However, whether speciﬁc autophagy inhibition
affects energy metabolism or survival at the level of leukemia
stem or progenitor cells is currently unknown.
Here we present novel ﬁndings regarding the mechanism
through which autophagy regulates energy metabolism and reac-
tive oxygen species (ROS)-dependent differentiation of CML
cells. Firstly we show that ATG7-mediated and/or pharmacologi-
cal autophagy inhibition in CML cells leads to a decrease in gly-
colysis and an increased ﬂow of labeled carbons through the
TCA cycle. This in turn leads to increased aerobic metabolism
and mitochondrial respiration. Additionally, we show for the ﬁrst
time that following autophagy inhibition a metabolic switch from
glycolysis to OXPHOS leads to ROS-dependent differentiation of
CML cells. Finally, we show that ATG7 knockdown sensitizes
CML CD34C cells to TKI-induced death, without affecting non-
CML CD34C cells, further supporting the concept that autophagy
is an important therapeutic target in CML.
Results
Autophagy inhibition leads to increased metabolic ﬂux
through the TCA cycle
An emerging theme is that autophagy exerts major homeostatic
control on cellular metabolism.15,23 Cellular metabolism can be
assessed by many complementary parameters, such as nutrient
(i.e., glucose) uptake, metabolite secretion rates and intracellu-
lar steady-state metabolite levels. Although steady-state meta-
bolic data is now relatively easy to generate, metabolic ﬂux (the
rate of conversion of one metabolite to another) is generally
considered the critical parameter in determining the activity of
a given metabolic pathway, such as glycolysis or the TCA
cycle.24 To examine intracellular ﬂux, heavy isotope (most fre-
quently 13C) labeled nutrients (tracers), such as uniformly
labeled glucose (U-13C6) are now commonly employed, which
can provide critical information regarding relative pathway
activities and nutrient contribution to the production of differ-
ent metabolites.25
Given the essential role of ATG7 in the autophagosome com-
pletion step (ATG7 encodes the E1-like enzyme required in both
ubiquitin-like LC3 and ATG12 conjugation systems) it is a ratio-
nal target to inhibit to investigate the effect of speciﬁc autophagy
inhibition on different cellular processes in cancer.26,27 To inves-
tigate the effect of speciﬁc autophagy inhibition on energy
metabolism in CML, K562 cells were transduced with a veriﬁed
short-hairpin RNA (shRNA) targeting ATG7 (shATG7)28 and a
scrambled shRNA as a control (shCtrl). mRNA levels revealed
89% knockdown of ATG7 in shATG7-expressing cells compared
with control (Fig. S1A). Following ATG7 knockdown inhibition
of autophagy was veriﬁed by measuring levels of LC3B-II (lipi-
dated form of LC3B—a marker for autophagosomes) and the
autophagy substrate SQSTM1/p6229,30 (Fig. S1B and C). We
then performed targeted metabolic analysis, focusing on glycoly-
sis (a process where glucose is broken down to 2 molecules of
pyruvate which are then either used to produce lactate or trans-
ferred to themitochondria) and the TCA cycle (Fig. 1A). Follow-
ing culture of shATG7 and control cells we initially quantiﬁed
the uptake and secretion of metabolites from the medium by liq-
uid chromatography-mass spectrometry (LC-MS). This revealed
a signiﬁcant decrease in glucose uptake and in lactate secretion
in shATG7-expressing cells, suggesting a reduction in aerobic
glycolysis (Fig. 1B and C). Additionally, there was an increase in
extracellular glutamate, a nonessential amino acid, which is gen-
erated from glutamine or by transamination of the TCA cycle
metabolite a-ketoglutarate (Fig. 1D), without any signiﬁcant
changes in glutamine uptake (Fig. 1E). We then cultured cells in
the presence of U-13C6 that gives an indication of ﬂux through
the metabolic pathways. Similar to Fig. 1B and C, shATG7 cells
consumed less U-13C6 and secreted less labeled lactate
(lactateC3) compared with control cells (Fig. 1F and G), further
suggesting decreased glycolytic ﬂux. Moreover, medium from
shATG7 cells contained increased levels of labeled glutamate,
which can only be generated following conversion of the labeled
glucose via a-ketoglutarate (Fig. 1H, see legends in Fig. 1A for a
description of metabolite labeling patterns). This suggested that
the TCA cycle was active in autophagy-deﬁcient cells.
We next measured the levels and contribution of glucose 13C
carbons to intracellular metabolites. While we observed no statis-
tical change in the levels or incorporation of 13C into the
glycolytic intermediates glucose-6-phosphate (glucose-6P), phos-
phoenolpyruvate (P-enolpyruvate) and pyruvate (Fig. 2A to C),
there was a decrease in the levels of 13C incorporation into lactate
(Fig. 2D). In contrast there was a signiﬁcant increase in the levels
of the TCA cycle intermediates, citrate and a-ketoglutarate, as
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well as glutamate (Fig. 2E to G). Importantly there was also an
increase in incorporation of 13C into citrate, a-ketoglutarate and
glutamate, suggesting that pyruvate is preferentially transferred
to the mitochondria (instead of being converted to lactate) lead-
ing to increased metabolic ﬂux through the TCA cycle (Fig. 2E to
G, i.e. see increase in isotopologues 13C4,
13C5 and
13C6-citrate;
this pattern can only be seen after a second and third round of
the TCA cycle as acetyl-coenzyme A conveys only 2 13C to the
ﬁrst round). To assess if autophagy inhibition also induced TCA
activity in primary cells, CML CD34C cells were treated with
HCQ in medium supplemented with physiological growth factors
(PGF) and U-13C6. Similar to results obtained in shATG7 K562
cells, HCQ-mediated autophagy inhibition led to increased incor-
poration of 13C into citrate, a-ketoglutarate and glutamate
(Fig. S2A to D) illustrating that this effect was not limited to the
K562 cells. Taken together, these data suggest that autophagy reg-
ulates the balance between nonmitochondrial and mitochondrial
energy pathways in CML cells.
Autophagy inhibition leads to an increase in
mitochondrial respiration
In light of the results generated above by LC-MS we sought to
understand more fully the effect of autophagy inhibition on
energy metabolism in real time using the Seahorse Extracellular
Flux Analyzer. This revealed a signiﬁcant decrease in extracel-
lular acidiﬁcation rate (ECAR) in shATG7-expressing cells
(Fig. 3A) in line with data in Fig. 1C and G showing decreased
secretion of lactate into the culture medium. These results con-
ﬁrmed that autophagy deﬁcient K562 cells are less glycolytic
compared with their autophagy competent cells. Secondly,
since the TCA cycle supplies reducing agents that are fed into
the mitochondrial electron transport chain (ETC) to further
drive ATP synthesis, we asked if upon ATG7 knockdown K562
cells increased OXPHOS to sustain energy demands and poten-
tially compensate for the inhibition in autophagy and the
reduction in aerobic glycolysis. Following measurements of
Figure 1. ATG7 knockdown affects extracellular metabolite levels. (A) A schematic diagram of energy metabolism in mammalian cells: During glycolysis, glucose (that
contains 6 carbons) is converted into 2 molecules of the 3-carbon metabolite pyruvate via a series of intermediate metabolites. Pyruvate can then either be used to pro-
duce lactate (3-carbon molecule which is often secreted from cells) or transferred to the mitochondria for further breakdown in the TCA cycle. The TCA cycle is a series of
chemical reactions, which leads to generation of energy through the oxidation of acetate (in the form of acetyl coenzyme A; acetyl Co-A) into carbon dioxide (CO2) and
energy in the form of ATP, which is synthesized following OXPHOS in the mitochondrial ETC. U-13C6 can be used to examine ﬂow of labeled carbons (indicated by red
circles) through these pathways. During the conversion of 3-carbon pyruvate to acetyl Co-A, one carbon is converted to CO2 such that acetyl Co-A maintains 2 pyruvate-
derived carbons (labeled) when it enters the TCA cycle. This can lead to build up of labeled carbons in TCA cycle intermediates when the pathway is activated. (B to H)
shATG7-expressing K562 cells were cultured in normal medium (B to E) or in the presence of U-13C6 (F to H). Extracellular glucose (B and F), lactate (C and G), glutamate
(D and H) and glutamine (E) were measured in the medium by LC-MS following 24 h culture. Note, the signiﬁcance levels for metabolites with variable labeled carbons,
(i.e. GluC1 D> glutamate C 1 £ 13C) are indicated in ﬁgure legends to the right of the graph: C1, etc. corresponds to glutamate containing 1X, etc. 13C. Two indepen-
dent experiments were performed in triplicate. P values: , P  0.05; , P  0.01; , P  0.001.
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mitochondrial respiration by oxygen consumption rate (OCR)
we observed a signiﬁcant increase in the basal, ATP-linked
(basal minus oligomycin-treated cells) and maximal OCR in
shATG7-expressing cells (Fig. 3B; S3A), showing that ATG7-
mediated autophagy inhibition not only resulted in increased
ﬂux through the TCA cycle, but also in a parallel increase in
OXPHOS. Similar increase in mitochondrial respiration was
observed in the Philadelphia-chromosome-positive KCL22 cell
line following ATG7 knockdown (Fig. S3B). To test if this was
an ATG7-speciﬁc effect we measured glycolysis and basal
OXPHOS following pharmacological autophagy inhibition.
HCQ replicated the effect of ATG7 knockdown, further sug-
gesting that autophagy regulates cellular energy metabolism in
CML (Fig. 3C and D; S3C). Finally, we measured the intracellu-
lar ATP levels in shATG7 and control cells (either grown in
normal medium or with U-13C6). This revealed that despite the
reduced glucose uptake by shATG7 cells (Fig. 1B and F) the
steady-state levels of ATP were unchanged and the incorpo-
ration of 13C carbons was comparable or slightly increased
(Fig. 3E and F). This suggests that autophagy deﬁcient CML
cells may either compensate for the reduction in energy gener-
ated by glycolysis by increasing OXPHOS, or increased
OXPHOS-mediated ATP generation in shATG7-expressing
cells leads to decreased glucose uptake and aerobic glycolysis.
Autophagy inhibition and elevated OXPHOS lead to an
increase in mitochondrial ROS
Since the principal source of ROS in the cell is the ETC we
hypothesized that the increased OXPHOS in autophagy deﬁ-
cient CML cells would lead to an increase in mitochondrial
ROS. In line with previous ﬁndings,31-34 after staining of K562
cells with TMRM and MTR; ﬂuorescent dyes that are seques-
tered by active mitochondria dependent upon membrane poten-
tial, shATG7-expressing cells showed a signiﬁcant increase in
TMRM and MTR staining (Fig. 4A and B), suggesting
impairment in autophagy-mediated degradation of mitochon-
dria. Similarly, an increase in different mitochondrial proteins
was also observed in shATG7-expressing cells (Fig. S4A). To fur-
ther conﬁrm that this was due to reduced clearance of active
mitochondria, we costained cells with MTR and the lysosomal-
associated membrane protein 1 (LAMP1). Calculations of coloc-
alization coefﬁcient revealed decreased overlap of LAMP1 and
MTR in shATG7-expressing cells (despite an increase in both
MTR and LAMP1 staining), further supporting the evidence for
impaired autophagy-mediated degradation of active mitochon-
dria in these cells (Fig. 4C; S4B). We then stained cells with
MitoSox Red to measure mitochondrial superoxide levels.
shATG7-expressing cells showed a signiﬁcant increase in super-
oxide levels when compared with control cells (Fig. 4D). Treat-
ment of K562 cells with HCQ, alone and in combination with
the antioxidant N-acetyl-L-cysteine (NAC), conﬁrmed that
autophagy inhibition leads to an increase in mitochondrial ROS
production (Fig. 4E; representative histogram in S4C). To assess
if autophagy inhibition also induced ROS in primary cells, CML
CD34C cells were cultured in medium supplemented with PGF
and treated with HCQ for up to 5 d (d). HCQ-mediated autoph-
agy inhibition increased MitoSox staining indicating an increase
in mitochondrial superoxide levels (Fig. 4F). Moreover, to assess
if changes in energy metabolism (switch from glycolysis to
OXPHOS) were sufﬁcient to increase ROS production in CML
cells we “forced” metabolic changes by altering the composition
Figure 2. Autophagy inhibition affects intracellular metabolite levels. (A to G) ShATG7-expressing K562 cells were cultured in the presence of U-13C6 for 24 h. Following
cell lysis, intercellular levels and incorporation of labeled carbons in glucose-6P (G6P) (A), P-enolpyruvate (PEP) (B), pyruvate (Pyr) (C), lactate (Lac) (D), citrate (Cit) (E),
a-ketoglutarate (aKG) (F) and glutamate (Glu) (G) was measured by LC-MS. Two independent experiments were performed in triplicate. , P  0.05; , P  0.01; ,
P  0.001. C2, etc. corresponds to metabolite containing 2X, etc. 13C.
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of the culture media or by inhibiting essential components of the
metabolic pathway. Culturing cells in galactose (instead of glu-
cose) as the sole sugar source forces mammalian cells to induce
and rely on OXPHOS for ATP synthesis.35,36 To examine
whether a metabolic switch from glycolysis to OXPHOS is
sufﬁcient to increase ROS production, K562 cells were cultured
in normal glucose-rich medium or in the presence of galactose.
This resulted in an increase in OCR and simultaneous decrease
in ECAR (Fig. 4G; S4E) and increased ROS production (Fig. 4H;
S4D). To further verify that an increase in OXPHOS leads to an
Figure 3. Autophagy inhibition reduces glycolysis and induces OXPHOS. ECAR (A) and OCR (B) were measured in shATG7-expressing cells using the Seahorse Extracellular
Flux Analyzer. Glycolysis (relative to shCtrl-expressing cells) was calculated as “average ECAR following glucose addition minus average ECAR following inhibition of gly-
colysis using 2-DG.” Relative mitochondrial respiration was calculated as “basal OCR minus OCR following antimycin and rotenone (ETC inhibitors) treatment (legends for
Fig. S3 provide more details). Three independent experiments were performed in quintuplicate. ECAR (C) and OCR (D) were measured in K562 cells following 24 h 10 mM
HCQ treatments. Two independent experiments were performed in quintuplicate. (E and F) ShATG7-expressing K562 cells were cultured in the absence (E) or presence (F)
of U-13C6 for 24 h. Following cell lysis, intercellular levels and incorporation of labeled carbons in ATP was measured by LC-MS. Two independent experiments were per-
formed in triplicate. , P  0.05; , P  0.01; , P  0.001. C2, etc. corresponds to ATP containing 2X, etc. 13C.
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increase in ROS production K562 cells were treated with 2 and
4 mM oxamate, an inhibitor of lactate dehydrogenase,37 direct-
ing pyruvate toward oxidation in the mitochondria. In line with
results obtained from cells grown in galactose, oxamate-treated
cells increased MitoSox staining suggesting that a metabolic
switch from glycolysis to OXPHOS is sufﬁcient to increase leak-
age of superoxide from the mitochondria in K562 cells (Fig. 4I;
representative histogram in S4D).
Elevated OXPHOS drives ROS-mediated differentiation of
CML cells
It has been suggested that high ROS correlates with myeloid dif-
ferentiation of normal blood cells.38,39 K562 cells persist in cul-
ture in an undifferentiated state, but can spontaneously
differentiate toward erythroid, granulocytic or monocytic line-
ages, and are therefore commonly used to measure differentia-
tion.40 We therefore assessed if the increase in ROS production
correlated with erythroid differentiation by culturing K562 cells
in galactose followed by measurement of TFRC/CD71 (transfer-
rin receptor) and GYPA/GlyA (glycophorin A [MNS blood
group]) by ﬂow cytometry. This revealed an increase in TFRC
and GYPA expression in galactose-treated cells indicating
erythroid differentiation (Fig. 5A and B). Similar results were
obtained in cells treated with oxamate (Fig. 5C and D) or follow-
ing ATG7 knockdown (Fig. 5E and F; representative histogram
in S5A to C). Additionally, when shATG7-expressing cells were
analyzed macroscopically it was evident that they had turned
red, indicating increased hemoglobin production in keeping
with increased TFRC and GYPA expression (Fig. S5D). Similar
effect was seen following knockdown of BECN1/Beclin1,
another key autophagy protein,41 demonstrating that the effect
was not restricted to knockdown of ATG7 (Fig. S5E). To con-
ﬁrm that the differentiation was driven by ROS, we cultured
shATG7-expressing cells with NAC followed by measurements
of differentiation. This revealed that NAC partially inhibited dif-
ferentiation driven by shATG7 by reducing TFRC expression to
similar levels as untreated control (Fig. 5G; representative histo-
gram in S5F). Similarly, HCQ induced ROS-dependent differen-
tiation of K562 cells (Fig. 5H).
Primary CP CML CD34C cells contain a mixture of CML
stem cells, multipotent and committed progenitor cells that
lose CD34C expression and differentiate when cultured in vitro.
To assess if autophagy inhibition further promotes differentia-
tion of primary cells, CD34C CML cells were cultured in the
presence of HCQ. HCQ-mediated autophagy inhibition led to
Figure 4. Elevated mitochondrial respiration induces ROS accumulation in CML cells. (A-B) levels of active mitochondria were measured in shATG7-expressing cells follow-
ing staining of cells with TMRM (A) and MTR (B) using ﬂow cytometry. (C) Colocalization of active mitochondria and lysosomes was measured in shATG7-expressing cells
following staining of cells with MTR and LAMP1 using confocal microscopy. (D to F, as well as H and I) mitochondrial superoxide levels were measured by MitoSox staining
in shATG7-expressing cells (D), K562 cells following 72 h 10 mM HCQ treatment alone and in combination with 10 nM NAC (E), CP CML CD34C cells (n D 3) following 72 h
10 mM HCQ (F), K562 cells cultured in the presence of glucose (normal medium) or galactose for 72 h (H) and K562 cells treated with 2 and 4 mM oxamate for 72 h (I).
Three independent experiments (A-F, H-I) were performed in duplicate. (G) OCR was measured in K562 cells cultured in the presence of 11 mM glucose or 11 nM galac-
tose for 72 h. Three independent experiments were performed in quintuplicate. , P  0.05; , P  0.01; , P  0.001.
AUTOPHAGY 941
an increase in TFRC and GYPA expression and a decrease in
CD34C expression, indicating that CML progenitor cells differ-
entiate toward the erythroid lineage upon autophagy inhibition
(Fig. 5I and J; S5G). Overall these data illustrate that autophagy
inhibition results in a metabolic shift from glycolysis to
OXPHOS in CML cells, leading to increased ROS production
followed by differentiation.
ATG7-mediated autophagy inhibition abrogates survival
of CML CD34C progenitor cells and sensitizes them to TKI-
induced cell death
In light of these results, we sought to understand more fully the
fate of patient-derived CML cells following speciﬁc autophagy
inhibition. To examine whether prolonged speciﬁc autophagy
inhibition affects survival of CML CD34C cells, shATG7 was
cloned into a GFP lentiviral construct42 to allow immediate
selection of shATG7-expressing cells. Following transduction of
CP CD34C cells with high titer lentivirus, autophagy inhibition
was veriﬁed by western blotting on unsorted cells (Fig. S6A)
and by counting the number of autophagy-related vesicles per
cell by electron microscopy cells following sorting based on
GFP expression (Fig. 6A). To move our results closer to the
clinic and measure the effect of ATG7 knockdown, alone or in
combination with TKI treatment, on expansion of CP CML
CD34C cells, GFP sorted cells were left untreated or treated
with nilotinib or dasatinib for 3 d. This revealed that ATG7
knockdown alone inhibited expansion of CML CD34C cells
and combination of either nilotinib or dasatinib with ATG7
knockdown further inhibited cellular expansion (although the
effect did not reach statistical signiﬁcance; Fig. S6B). To mea-
sure the effect of ATG7 knockdown on survival of CML pro-
genitor cells, GFP sorted cells were plated into methylcellulose-
based medium in the presence or absence of TKIs. Colonies
were counted 14 d later and revealed that stable ATG7 knock-
down alone signiﬁcantly reduced their numbers to a similar
extent as nilotinib treatment alone (Fig. S6C). Importantly,
shATG7-expressing cells were sensitized to TKI-induced death,
with the difference between nilotinib alone versus nilotinib
with ATG7 knockdown reaching statistical signiﬁcance. The
same effect was seen when GFP sorted cells were treated for 3
or 6 d in liquid culture, followed by drug washout, before being
plated into colony forming cell (CFC) assay (Fig. 6B and C).
This demonstrated that TKI treatment directly affected survival
of progenitor cells following ATG7 knockdown.
Given the detrimental effect of Atg7 deletion in HSC in
mouse models31 and in an attempt to anticipate possible myelo-
suppression in the clinic for the combination of TKI with spe-
ciﬁc autophagy inhibition, we assessed the effect of ATG7
knockdown on primary human non-CML CD34C cells. Non-
CML CD34C cells were transduced with shATG7 lentiviruses
and following sorting of GFP-positive cells the effect of ATG7
knockdown alone, or in combination with TKI treatment, on
proliferation, apoptosis and CFC potential was measured.
Unlike in CML cells, ATG7 knockdown had little effect on pro-
liferation, apoptosis or CFC potential of non-CML cells,
Figure 5. Enhanced OXPHOS drives differentiation of K562. (A to H) cellular proﬁle was analyzed in K562 by ﬂow cytometry for expression of TFRC (A, C, E, G and H) and
GYPA (B, D and F) following 5 d culture in galactose (A and B), 5 d treatment with 2 mM and 4 mM oxamate (C and D), ATG7 knockdown alone (E and F) or C/¡ 10 nM
NAC treatment (G) or 72 h 10 mM HCQ treatmentC/¡ 10 nM NAC (H). Three independent experiments were performed in duplicate. (I and J) TFRC (I) and GYPA (J) levels
were measured in CP CML CD34C cells (n D 3) following 72 h 10 mM HCQ treatment. , P  0.01; , P  0.001.
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whether or not combined with TKI (Fig. 6D; S6D and E).
Taken together these data indicate that TKI treatment com-
bined with speciﬁc autophagy inhibition should achieve selec-
tivity toward leukemic over normal progenitor cells.
Discussion
The ﬁndings we present in this study are that following ATG7-
mediated autophagy inhibition, CML cells switch from glycoly-
sis to mitochondrial respiration, indicating that autophagy
plays a role in maintaining the Warburg effect (i.e., production
of energy by a high rate of aerobic glycolysis followed by lactic
acid fermentation in the cytosol) in leukemic cells. The
increased mitochondrial respiration was linked with an
increase in mitochondrial membrane potential and ROS levels,
suggesting decreased clearance of active mitochondria. This
phenotype was also seen following HCQ treatment, demon-
strating that the effect of ATG7 knockdown in our CML model
resulted from inhibition of autophagy rather than by affecting
autophagy-independent roles of ATG7. Furthermore, we
showed that inhibition of autophagy and elevated OXPHOS
affected differentiation of K562, KCL22 and primary CD34C
cells, with autophagy deﬁcient cells differentiating toward the
erythroid lineage. However, whether this would affect genera-
tion of fully enucleated red blood cells and provide a potential
explanation of the severe anemia observed in mice lacking
ATG7 in the hematopoietic system33 remains to be investi-
gated. Additionally, given that recent ﬁndings demonstrated
that BCR-ABL can be an autophagy substrate following arsenic
trioxide or TKI-induced autophagy,19,43 it remains to be tested
whether autophagy inhibition affected the levels or activity of
BCR-ABL in our systems, thereby potentially promoting the
enhanced ROS-mediated differentiation.
Increasing evidence suggests that ROS, which have previ-
ously been shown to be critical regulators of differentiation of
normal blood cells, can act as signaling molecules.44 Studies in
Drosophila have shown that increasing ROS beyond their nor-
mal levels in progenitor cells triggers differentiation by a
mechanism that involves the MAPK8/JNK1-MAPK9/JNK2-
MAPK10/JNK3 signaling pathway.38 Although the molecular
mechanism by which ROS induces myeloid differentiation in
our cells is not clear, it is tempting to speculate that ROS may
also induce differentiation through activation of MAPK8/9/10.
Indeed, increased ROS levels have previously been demon-
strated to activate the MAPK8/9/10 signal transduction path-
way in CML cells, as well as in unrelated systems.44-49
Our results also suggest that the role of autophagy in differ-
entiation of leukemic cells may be cell type and/or disease spe-
ciﬁc since in promyelocytic leukemia, a subtype of acute
myeloid leukemia, inhibition of autophagy attenuates all-trans
retinoic acid-induced neutrophil differentiation,50-52 and phar-
macological induction of autophagy potentiates all-trans reti-
noic acid-induced myeloid differentiation in acute myeloid
leukemia.53 This underlines that different strategies may be
required to exploit autophagy for various cancer types in the
clinic.
We have previously shown that pharmacological inhibition
of autophagy using chloroquine (CQ) enhances the efﬁcacy of
TKI against CML stem and progenitor cells.21,22 However,
recent in vitro studies show that the ability of CQ to enhance
chemotherapeutic responses is the same whether the cells are
autophagy competent or deﬁcient.54 This raises the question
whether the therapeutic effects of CQ or HCQ were related to
Figure 6. ATG7 knockdown enhances the effects of TKI treatment on survival of CP CML CD34C cells. Following ATG7 knockdown CP CML CD34C (A to C, nD3) or non-
CML CD34C cells (D, n D 3) were sorted based on GFP expression. (A) The number of autophagy-related vesicles (ﬁlled double membrane vesicles, indicated with black
arrows) was quantiﬁed using electron microscopy (total of 9 cells per arm). Representative pictures are shown. (B to D) The clonogenic ability of shCtrl or shATG7 CD34C
cells was evaluated by transferring cells to semisolid media following treatment with TKI for 3 d (B, D) or 6 d (C).
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inhibition of autophagy at all. Although our previous studies in
CML cell lines suggest that the effects of CQ are at least in part
due to autophagy inhibition, this has not been tested in primary
cells. Here we conﬁrmed that stable and speciﬁc autophagy
inhibition was detrimental for survival of primary CML. Inter-
estingly, this dependency on ATG7 for survival was not seen
following ATG7 knockdown in normal CD34C cells. However,
whether the difference in phenotypes following atg7 knockout
in mice31 vs. ATG7 knockdown in human cells reﬂects different
roles of ATG7 depending on the environment (stem cells
within the bone marrow niche in mice vs. cultured in vitro),
developmental stage (atg7 knockout mice are born autophagy-
deﬁcient) or techniques used (complete knockout vs. partial
knockdown) remains to be explored. Of clinical importance,
we also showed that ATG7 knockdown enhanced the effect of
the second generation TKIs nilotinib and dasatinib, suggesting
that the combination of speciﬁc autophagy inhibition and TKI
treatment might lead to deeper response rates in CML patients
with increased chance of successful drug discontinuation or
even cure. Indeed, although no speciﬁc autophagy inhibitors
are currently available for clinical use, with increasing under-
standing of the main regulators of each step of the process,
some critical players appeal as attractive drug targets, such as
the kinases in the ULK1 protein complex, PIK3C3, the catalytic
subunit of the class III phosphatidylinositol 3-kinase, (whose
yeast ortholog is Vps34) and essential “druggable” ATG pro-
teins, such as ATG4 and ATG7 (preclinical inhibitors of some
of these targets are already being developed in academia or
industry).55-59 Therefore future examination should focus on
the effect of inhibiting these proteins in a speciﬁc manner in
order to ﬁnd the most suitable autophagy target in CML.
Materials and methods
In vitro cell culture
K562 and KCL22 cells were cultured in RPMI 1640medium, sup-
plemented with 1% (vol/vol) penicillin/streptomycin (10,000 mg/
mL/10,000U/mL, Invitrogen, 15140–122), 1% L-glutamine (Invi-
trogen, 25030–024), and 10% (vol/vol) fetal calf serum (Invitro-
gen, 10500). CP CML and non-CML CD34C cells were cultured
in serum-free medium comprising Iscove-modiﬁed Dulbecco
medium with BIT (bovine serum albumin, insulin, transferrin;
STEMCELL Technologies, 09500), 2 mmol/l glutamine, 1 mmol/l
streptomycin/penicillin, 40 ng/ml low-density lipoprotein and
0.1 mmol/l 2-mercaptoethanol (Invitrogen, 21985–023). CP
CML CD34C cells were further supplemented with a PGF cock-
tail; 0.2 ng/mL SCF/GM-CSF/MIP-a, 1.0 ng/mL G-CSF/IL6
(PeproTech EC Ltd, 300–07, 300–03, 300–08, 300–23 and 200–06)
and 0.05 ng/mL LIF, (STEMCELL Technologies, 02642). Non-
CMLCD34C cells were either cultured in PGFmedium or further
supplemented with a high-growth factor cocktail; 20 ng/mL IL3/
IL6/G-CSF and 100 ng/mL Flt3L/SCF.
Primary cell CD34 enrichment
Primary cells were obtained with informed consent from leuka-
pheresis samples of newly diagnosed patients with CP CML or
Philadelphia-chromosome-negative B cell haematological dis-
orders. CD34C cells were enriched as previously described.21
Western blotting
Western blotting was performed using antibodies against p-CRKL
(Cell Signaling Technology, 3181), LC3B (Cell Signaling Technol-
ogy, 2775) TUBB/b-tubulin (Cell Signaling Technology, 2146),
SQSTM1 (BD Biosciences, 610833), ATG7 (Epitomics, 2054–1)
and Membrane Integrity WB Antibody Cocktail (Abcam,
ab110414). Primary antibody detection was by enhanced chemilu-
minescence (GE Healthcare/Amersham, RPN2106) using a horse-
radish peroxidase-linked secondary antibody (Cell Signaling
Technology, 7074 and 7076).
Measurements of ECAR and OCR
ECAR and OCR were measured using the Seahorse XF96 Flux
Analyzer (Seahorse Bioscience, 2100 Copenhagen, Denmark).
The XF96-well plate was coated with 25 mL per well of a Cell
Tak solution (22.6 ug/mL; Corning, 354240) and left for at least
30 min at room temperature. The day after K562 cells were
seeded in each well in 35 mL of XF Assay Medium (Seahorse
Bioscience, 100965–000) supplemented either with 2 mM glu-
tamine for ECAR measurement or 2 mM glutamine, 11 M glu-
cose for OCR analysis. After 30 min incubation 140 mL of
medium were added to each well and the plate loaded on the
analyzer after an additional 30 min incubation. The concentra-
tions of drugs added into the cell plate during the experiment
were 10 mM glucose, 10 mM 2-deoxy-D-glucose (2-DG),
1 mM oligomycin (an ATP synthase inhibitor; Sigma-Aldrich,
75351), 0.6 mM FCCP (uncouples mitochondria; Sigma-
Aldrich, C2920), and 1 mM rotenone (Sigma-Aldrich, R8875)
and 1 mM antimycin A (both ETC inhibitors; Sigma-Aldrich,
A8674). Each time point was calculated as an average from at
least 6 replicates. Error bars represent average C/¡ SD. Data
shown are a representative experiment that was conﬁrmed in 3
independent experiments.
LC-MS analysis
A Thermo Scientiﬁc Exactive Orbitrap mass spectrometer was
used together with a Thermo Scientiﬁc Accela HPLC system
(Thermo Scientiﬁc Waltham, MA, USA). The HPLC setup con-
sisted of a ZIC-pHILIC column (SeQuant 150£2.1 mm, 5 mm,
1.50460.0001, Merck KGaA, Darmstadt, Germany), with a ZIC-
pHILIC guard column (SeQuant 20 x2.1 mm, 1.50438.0001,
Merck KGaA, Darmstadt, Germany) and an initial mobile phase
of 20% 20 mM ammonium carbonate, pH 9.4 (Sigma-Aldrich,
74415), and 80% acetonitrile (VWR, HiperSolv Chromanorm,
83639.320). Cell and media extracts (5 ml) were injected and
metabolites were separated over a 15-min mobile phase gradi-
ent, decreasing the acetonitrile content to 20%, at a ﬂow rate of
200mL/min and a column temperature of 45C. The total analy-
sis time was 23 min. All metabolites were detected across a mass
range of 75 to 1000 m/z using the Exactive mass spectrometer at
a resolution of 25,000 (at 200m/z), with electrospray ionization
and polarity switching to enable both positive and negative ions
to be determined in the same run. Lock masses were used and
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the mass accuracy obtained for all metabolites was below 5 ppm.
Data were acquired with Thermo Xcalibur software.
The peak areas of different metabolites were determined
using Thermo TraceFinder software where metabolites were
identiﬁed by the exact mass of the singly charged ion and by
known retention time on the HPLC column. Commercial
standards of all metabolites detected had been analyzed previ-
ously on this LC-MS system with the pHILIC column. The 13C
labeling patterns were determined by measuring peak areas for
the accurate mass of each isotopologue of many metabolites.
Intracellular metabolites were normalized to cell number or
protein content of the cells, measured by BCA assay.
Flow cytometry
For measurements of mitochondrial function ATG7 knock-
down, K562 cells were stained with TMRM (a cell-permeant,
cationic, red-orange ﬂuorescent dye, Life Technologies, T-668)
and MitoTracker Red CMXRos (a reduced probe that does
not ﬂuoresce until it enters live cells, where it is oxidized and
sequestered in functional mitochondria and starts emitting red
ﬂuorescence, Invitrogen, M-7512). For ROS measurements
ATG7 knockdown or HCQ-treated cells were washed with
phosphate-buffered saline (PBS; Gibco, 14190–094, 18912–
014) and incubated with 5 mM MitoSoxTM Red (Invitrogen,
M36008) in PBS at 37C in the dark for 30 min. Cells were
then centrifuged (400 g for 5 min) and resuspended in PBS.
Fluorescence was detected by FACSVerse ﬂow cytometry (BD
Biosciences, 651155, San Jose, CA, USA). For assessment of dif-
ferentiation K562 and CML CD34C cells were stained with
ﬂuorochrome-conjugated mAbs directed against CD34 (BD
Biosciences, 555824), TFRC (BD Biosciences, 555537) and
GYPA (BD Biosciences, 561776). Data analyses were per-
formed using FlowJo software (Tree Star).
Cloning
The shATG7 hairpin was subcloned from the pLKO.1-puro-
shATG7 (TRCN0000007584; Sigma-Aldrich) vector into the
backbone of the pLKO.1-GFP using SpeI and NdeI restriction
sites. pLKO.1-GFP backbone and shATG7 insert were gel-puri-
ﬁed by using the QIAquick Gel Extraction Kit (Qiagen, 28704)
and ligated overnight at room temperature.
Lentivirus production and transduction
pLKO.1 transfer vector containing veriﬁed shRNA speciﬁc
for human ATG7 (or nontargeting scrambled hairpin as con-
trol), pCMV-VSV-G and psPAX2 plasmids were transfected
into HEK293 cells using the CaCl2 method as previously
described.10 Transduction of K562 cells was performed with ﬁl-
tered unconcentrated virus with 70% to 95% of the cells
expressing GFP after 48 h. Primary human CD34C cells were
transduced for 3 rounds with ﬁltered unconcentrated lentivirus.
Virus transduction reagent TransduxTM (Lonza, LV850A-1)
was used to increase transduction efﬁciency;48 to 72 h follow-
ing the third infection, cells were selected by ﬂow cytometry
based on GFP expression and cultured in medium containing
PGF.
Reagents
Imatinib and nilotinib were provided by Novartis Pharma
(Basel, Switzerland). Dasatinib was provided by Bristol-Myers
Squibb (Princeton, NJ, USA). Stock solution of 100 mM imati-
nib was prepared in sterile distilled water and stored at 4C.
Stock solutions of 10 mM nilotinib and 10 mM dasatinib were
prepared in dimethyl sulphoxide (Sigma-Aldrich, A3912 100)
and stored in aliquots at ¡20C.
CFC assay
Following in vitro drug treatment 5,000 cells were added to
3 mL of Methocult
TM
H4434 medium (STEMCELL Technolo-
gies, 04434). Then 1.5 mL was transferred to a 35 mm tissue
culture dish in duplicate. After 14 d the number of viable colo-
nies was counted in each dish.
Immunoﬂuorescence and confocal microscopy
ShCtrl and shATG7 K562 cells were incubated with 50 nM
MitoTracker Red CMXRos (Invitrogen, M-7512) for 20 min
at 37C. After washing out the stain the cells were plated on
poly-l-lysine (Sigma-Aldrich, P4707) precoated multispot
microscope slides (Hendley-Essex, PH-088). Cells were ﬁxed
with 3.7% formaldehyde for 15 min, and permeabilized with
0.5% Triton X-100 (Sigma-Aldrich, T8787) during 10 min.
After applying blocking solution (5% BSA [Sigma-Aldrich,
A3912] in PBS) the slides were incubated with LAMP1-AF488
antibody (1:100; Santa Cruz Biotechnology, 20011) overnight
at 4C (isotype control was included in every experiment).
Mounting media with DAPI was used for nuclei staining and
slides were analyzed using Zeiss LSM 780 confocal microscope
(07745 Jena, Germany). Images were collected at 40x and 63x
and the colocalization coefﬁcient was calculated using Micro-
scope and Imaging Software ZEN 2.1.
Statistical analysis
Statistical analysis was performed by using unpaired Student t
tests. A level of P less than or equal to 0.05 was taken to be sta-
tistically signiﬁcant (, P0.05; , P0.01; , P0.001). Error
bars in all ﬁgures represent standard deviation.
Abbreviations
acetyl Co-A acetyl coenzyme A
CFC colony forming cell
CML chronic myeloid leukemia
CP chronic phase
CQ chloroquine
2-DG 2-deoxy-D-glucose
ECAR extracellular acidiﬁcation rate
ETC electron transport chain
glucose-6P glucose-6-phosphate
GYPA/GlyA glycophorin A (MNS blood group)
HCQ hydroxychloroquine
HSC haemopoietic stem cell
LAMP1 lysosomal-associated membrane protein 1
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LC-MS liquid chromatography-mass spectrometry
MAPK mitogen-activated protein kinase
MTR MitoTracker Red
NAC N-acetyl-L-cysteine
OCR oxygen consumption rate
OXPHOS oxidative phosphorylation
p-enolpyruvate phosphoenolpyruvate
PBS phosphate-buffered saline
PGF physiological growth factors
ROS reactive oxygen species
shCtrl scrambled shRNA as a control
shRNA short-hairpin RNA
TCA tricarboxylic acid
TKI tyrosine kinase inhibitor
TMRM tetramethylrhodamine, methyl ester
U-13C6 uniformly labeled glucose
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